Global Medical Device Regulatory Update, October 2026: 27 Official Developments

Global Medical Device Regulatory Update – October 2026 edition. Scope: 10 core markets + 25 emerging markets | Search window: October 1-31, 2026 (based on each authority’s official publication date) | Our regulatory affairs team verified 27 official documents and official-channel sources this month

Foreword

Hello, this is our global registration and compliance team.

Starting with this issue, we will regularly review regulatory changes across the world’s major medical device markets in a monthly/weekly format. For every item, we require verification against the original text published by the responsible authority before it goes into the main report; leads we could not verify against official sources are listed separately and clearly marked – we never present them as confirmed information. After many years of handling overseas registrations, our experience is that one wrong compliance call can cost a company a full year of work. That is why this monthly report would rather carry fewer items than include a single entry of unclear or unreliable origin.

October was a genuinely big month. The UK formally announced indefinite recognition of CE-marked medical devices and IVDs, China’s new GMP and its full set of accompanying inspection guidance all landed, the EU’s EUDAMED SSCP upload responsibility handover entered its countdown, and Japan’s PMDA submission system went offline indefinitely after a security incident – any one of these is enough to affect submission schedules and documentation strategy in the corresponding market.

Here is the main report.

I. Five Highlights of the Month (30-Second Overview)

• UK: On October 21 the government formally confirmed indefinite recognition of CE-marked medical devices and IVDs for the GB market, with UKCA and CE running in parallel – for manufacturers already holding CE certificates, market entry costs for the UK drop substantially.
• China: The newly revised Medical Device GMP takes effect on November 1, and the five accompanying inspection guidance documents (sterile, implantable, IVD, custom dentures, standalone software) were published in quick succession in late October, with inspection items fully restructured.
• EU: MDCG 2026-4 rev.1 (October version) clarifies that SSCP/SSP upload responsibility shifts from notified bodies to manufacturers; the functionality is expected to go live in December, and March 27, 2027 is the key deadline.
• Japan: PMDA’s medical device web submission platform (DWAP) suffered unauthorized access between October 23-26 and is offline indefinitely; submissions must temporarily switch to MHLW’s FD application software.
• Brazil: ANVISA advanced three items in parallel – publication of the recognized technical standards list, a public consultation (CP 1248) on restructuring technical documentation for Class III/IV registrations, and targeted consultation on expanded MDSAP applicability.

II. Core Markets in Detail

01 China: New GMP takes effect in November; CMDE publishes intensive IVD and frontier device guidance

(1) NMPA issues 5 GMP inspection guidance documents, effective November 1 alongside the new regulation

• Matter: NMPA issued the ‘GMP Inspection Guidance for Sterile Medical Devices’ and three other inspection guidance documents (Guo Yao Jian Xie Guan [2026] No. 16, dated October 23, 2026), plus the ‘GMP Inspection Guidance for Standalone Software’ (Guo Yao Jian Xie Guan [2026] No. 17, dated October 30, 2026).
• Publication dates: October 28 and October 30, 2026 (official website posting dates).
• Effective dates: All effective from November 1, 2026, in sync with the newly revised Medical Device GMP; the former documents Shi Yao Jian Xie Jian [2015] No. 218, [2016] No. 165, and Yao Jian Zong Xie Guan [2020] No. 57 are repealed simultaneously.
• Key content: Inspection items are restructured into three tiers – critical (***), major (**), and general (*): 216 items for sterile devices (41 critical), 220 for implantable devices (43 critical), 212 for IVDs (42 critical), 190 for custom dentures (38 critical), and 203 for standalone software (41 critical). From November 1, both production license inspections and post-market supervision inspections are judged against the new guidance.
• Our take: For domestic manufacturers this is the single most important domestic development of October. The number of critical items determines the ‘life-or-death line’ of on-site inspections; we recommend manufacturers complete a self-assessment against the new guidance within November. Standalone software companies in particular should note that software-component inspections also follow the new guidance – SaMD vendors should not assume GMP is only a concern for hardware companies.
• Official sources:

• Notice on the four inspection guidance documents: https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/gzwj/gzwjylqx/20261028170125118.html Standalone software guidance notice: https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjylqx/20261030165430153.html

(2) CMDE publishes multiple registration review guidelines in October

• No. 27 (October 8): ‘Registration Review Guideline for Batteries of Active Implantable Medical Devices’ – review requirements for the core component of active implantable devices are now documented separately; pacemaker and implantable pump manufacturers should pay close attention.
• No. 28 (October 12): Registration review guidelines (2026 revised editions) for ‘HER2 gene amplification detection kits (fluorescence in situ hybridization method)’ and ‘Hepatitis C virus genotyping detection kits’ – both HER2 FISH and HCV genotyping are major IVD export categories; after the revised versions replace the old ones, projects under review or awaiting submission need documentation prepared to the new requirements.
• No. 29 (October 22): ‘Key Points for Clinical Trial Technical Review of Implantable Brain-Computer Interface Hand Motor Function Compensation Systems’ – clinical trial review standards for BCI devices are specified at this level of product concreteness for the first time, giving domestic innovative device companies a clearer submission path in this field.
• No. 30 (October 16): ‘Registration Review Guideline for Carbapenem-Resistance Gene bla_KPC Detection Kits’ – the review framework for AMR (antimicrobial resistance monitoring) IVDs is further completed.
• Open for comment (feedback required before deadlines): ‘Registration Review Guideline for Recombinant Collagen Products for Aesthetic Plastic Surgery (draft for comment)’ (October 21), ‘Registration Review Guideline for Aortic Covered Stent Systems’ (October 20), ‘Registration Review Guideline for Rigid Gas-Permeable Contact Lenses for Orthokeratology (draft for comment)’ (October 19).
• Official sources:

• No. 28 notice: https://www.cmde.org.cn/xwdt/shpgzgg/gztg/20261013100722185.html No. 30 notice: https://www.cmde.org.cn/xwdt/shpgzgg/gztg/20261022112612186.html All other documents and draft guidances for comment: https://www.cmde.org.cn/xwdt

02 United States: Multiple classification final orders take effect in the Federal Register; FY2027 guidance plan published

(1) Final orders on Class II device classification and 510(k) exemptions

• October 6: FDA issued a final order exempting certain Class II clinical toxicology test systems from 510(k) requirements (21 CFR 862, 91 FR 63478, FR doc. 2026-20448), effective upon publication. Companies working on IVDs related to federal drug testing programs see their submission burden reduced directly.
• October 6: Focused ultrasound systems for non-thermal, mechanical tissue ablation classified as Class II special controls (21 CFR 878, 91 FR 63493).
• October 8/9: Over-the-counter infant pulse rate and oxygen saturation monitors classified as Class II special controls and codified at 21 CFR 870.2705, effective October 9 – home infant monitoring products now have a clear regulatory pathway (510(k) required unless exempted later).
• Official sources:

• Clinical toxicology test system exemption order: https://www.govinfo.gov/content/pkg/FR-2026-10-06/html/2026-20448.htm Focused ultrasound classification order: https://www.govinfo.gov/app/details/FR-2026-10-06/2026-20440 Infant pulse rate and oxygen saturation monitor classification order: https://thefederalregister.org/documents/2026-20726/medical-devices-cardiovascular-devices-classification-of-the-infant-pulse-rate-and-oxygen-saturation-monitor-for-over-th

(2) CDRH publishes its FY2027 guidance work plan (October 1)

List A covers 7 final guidance documents plus 1 draft, with topics concentrated on AI device lifecycle management, predetermined change control plans (PCCPs), and surgical robots; the comment period runs until November 30, 2026. For companies bringing AI devices and software products to the US market, this is the window to submit comments to FDA – miss the comment period and you can only passively accept the final version.

(3) IDE electronic submission template (eSTAR) draft guidance (posted October 27)

Comment period until December 28, 2026. Companies submitting clinical trials via the IDE pathway will see submission templates go fully electronic.

• Official sources: CDRH news hub https://www.fda.gov/MedicalDevices/NewsEvents/News/default.htm | eSTAR draft: https://www.regulations.gov/document/FDA-2026-D-11188-0002

03 European Union: SSCP/SSP upload responsibility shifts to manufacturers; functionality live in December, deadline end of March next year

• Matter: MDCG published the position paper MDCG 2026-4 rev.1, ‘Management of SS(C)Ps in EUDAMED once its use becomes mandatory’ (October 2026 version).
• Core content: For Class III and implantable devices, responsibility for uploading the Summary of Safety and Clinical Performance (SSCP) to EUDAMED – and for Class C/D IVDs the Summary of Safety and Performance (SSP) – will shift from notified bodies to manufacturers; manufacturers must upload the validated ‘master version’ plus all translated versions, and notified bodies will instead confirm in EUDAMED which version is the validated one.
• Key dates: The functionality is expected to open to manufacturers in the EUDAMED production environment from December 2026; for devices placed on the market before May 28, 2026 (the mandatory EUDAMED use date), manufacturers should complete SS(C)P uploads no later than March 27, 2027.
• Our take: The document itself is not legally binding, but it represents the unified operational expectation between notified bodies and manufacturers, and implementation will follow it in practice. Three reminders: (1) manufacturers of CE-certified Class III/implantable devices – inventory now how many products need uploads and whether translations are complete; (2) those planning certificate renewals in the first half of 2027 – build SSCP uploads into the renewal timeline so certificate registration and document uploads do not fall out of sync; (3) companies heavily reliant on notified-body channels – once upload responsibility shifts to you, capabilities around EUDAMED accounts, XML formats, and UDI-DI linkage must be built up in advance.
• Official source: https://health.ec.europa.eu/document/download/a80332cf-e9f0-4d45-8863-3d96e8c2a675_en

04 United Kingdom: Indefinite recognition of CE marking formally confirmed – the biggest global news of the month

• Matter: On October 21, the UK government formally confirmed indefinite recognition of CE-marked medical devices and IVDs for circulation in the GB (Great Britain) market.
• Background: The decision is based on a targeted public consultation held February 16 – April 10, 2026 (over 1,000 responses received). More than 90% of registered medical devices on the GB market currently carry the CE mark.
• Key points: (1) CE and UKCA run in parallel, and CE is no longer a ‘transition arrangement’; (2) the UKCA route is being modernized in parallel (pre-market legislation being updated); (3) MHRA is strengthening post-market surveillance in step.
• Our take: For most manufacturers, the practical meaning of this news is that the UK market returns to the era of ‘direct entry with a CE certificate.’ Many companies had been anxious about the 2028/2030 UKCA deadlines; that uncertainty is now removed. Companies already holding CE certificates can immediately assess UK market opportunities; those not yet in the UK can treat it as a bonus market on their CE certification investment. Companion developments in the same period: the MHRA 2030 strategy (published October 14, a regulatory modernization roadmap for the AI and personalized medicine era) and AI medical device regulatory reform (October 6, the government accepted all 44 recommendations of the AI in Healthcare national committee in full, and the third round of the AI Airlock sandbox opened for applications).
• Official sources:

• Indefinite recognition of CE marking announcement: https://www.gov.uk/government/news/government-confirms-indefinite-recognition-of-ce-marked-medical-devices MHRA news hub: https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency

05 Japan: PMDA submission platform DWAP hit by unauthorized access, offline indefinitely

• Matter: PMDA announced that its medical device web submission platform (DWAP) suffered unauthorized access between October 23 and 26 and has been taken offline indefinitely, with no restoration date set (PMDA’s words: a considerable repair period is expected).
• Impact: No information leakage, data tampering, or destruction has been detected so far. During the outage, new submissions and change applications must use MHLW’s ‘FD application software’ (web.fd-shinsei.mhlw.go.jp) to prepare application forms and notifications.
• Our take: For companies in the middle of Japanese registrations, this is purely an ‘operational incident’ – the submission channel changed, but processes and documentation requirements did not. If you have Japanese projects in flight or submissions planned soon, confirm the channel switch with your Japan Marketing Authorization Holder/MAH immediately and build slack into your project schedule. Restoration dates follow PMDA’s official notices.
• Official source: https://www.pmda.go.jp/ (see the ‘What’s New’ section and system maintenance notices on the homepage)

06 Australia: TGA draws the medical device boundary for ‘digital scribe’ tools

• Matter: On October 16, TGA published the results of its targeted review of digital scribes (AI tools that listen in clinical environments and draft clinical documentation) together with updated regulatory guidance.
• Core finding: Of the 12 products reviewed, 8 included functions that may fall within the medical device definition under Section 41BD of the Therapeutic Goods Act 1989 – yet none of the 12 suppliers had proactively identified their product as a medical device. The updated guidance provides a yes/no medical device comparison table covering 7 categories of functions.
• Companion development: Amendments to the clinical decision support system (CDSS) exemption were finalized at the same time, effective November 1, 2026 – the exemption scope is unchanged, but its boundaries are now clearer.
• Our take: This move is the latest statement by any regulator worldwide on the ‘boundary of AI clinical software,’ with reference value well beyond Australia. Companies taking AI medical software overseas can use the 7-function table to self-check their products – functions such as ‘generating diagnostic or treatment recommendations’ or ‘deriving diagnostic conclusions from coded outputs’ are regulatory red lines.
• Official sources:

• CDSS exemption amendments: https://tga.gov.au/news/news-articles/clinical-decision-support-system-exemption-amendments TGA news hub: https://tga.gov.au/news/whats-new

07 Canada: New device shortage and discontinuation reporting rules published, effective June 2027

• Matter: On October 7, Health Canada published the revised guidance GUI-0137 v4 (shortage and discontinuation reporting) and GUI-0147 v2 (exceptional importation and sale in response to shortages); on October 16 it issued a companion compliance bulletin (MDC Bulletin) and held a webinar.
• Key changes (GUI-0137 v4, effective June 17, 2027):

• All reporting clocks change from ‘business days’ to calendar days; Expected shortages identified more than 6 months in advance must be reported at least 6 months before the shortage begins; The scope of discontinuation reporting is expanded – all discontinuations of listed devices must be reported (previously only those likely to cause a shortage), and discontinuations decided more than 12 months in advance must be reported at least 12 months ahead; The exemption where ‘an alternative product exists’ is removed; The exemption for shortages of 30 days or less is retained.
• Our take: Canada is not a frontline market for most device companies, but these new rules deserve a read by every regulatory team doing global post-market management – the combination of ‘calendar days + advance reporting + full discontinuation reporting’ reflects the global regulatory trend toward tighter supply chain transparency, and the EU and UK are moving in similar directions. Companies holding an MDEL or selling products in Canada must rework their internal shortage monitoring and reporting SOPs before June 2027.
• Official sources:

• Compliance bulletin (2026-10-16): https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/establishment-licences/medical-devices-compliance-bulletin/updated-guidance-documents-medical-device-shortages.html GUI-0147 v2: https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/application-information/guidance-documents/guide-exceptional-importation-sale-medical-devices-response-shortages-0147.html

08 Brazil: ANVISA advances on three fronts – standards list, registration proposal, MDSAP

(1) Recognized technical standards list published (October 22): three workbooks – general/horizontal standards (60 items), orthopedic implant materials (88 items), and materials for medical use (61 items) – covering ABNT/ISO/ASTM standards. Recognition is voluntary (unless mandated by health regulations), but it is a clear signal that ANVISA is aligning Brazil’s review baseline with international standards; technical documentation for Brazilian registrations can select standards accordingly.

(2) CP 1248 public consultation: a proposal to restructure the technical documentation framework for Class III/IV high-risk device registrations – the documentation table of contents aligns with the IMDRF ToC, with strengthened clinical evidence and risk management requirements. Companies holding or planning Class III/IV Brazilian registrations should study this consultation carefully and submit feedback – it directly determines the skeleton of future submissions.

(3) Targeted consultation on expanded MDSAP applicability (closes November 9): ANVISA is assessing whether to mandate/expand the applicability of MDSAP (Medical Device Single Audit Program) in Brazil, and is soliciting targeted feedback from companies on participation experience, costs, and impact.

• Official sources:

• ANVISA news hub (English): https://www.gov.br/anvisa/en/updates/ CP 1248 news: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/cp-propoe-nova-regra-para-registro-de-dispositivos-medicos

09 Saudi Arabia: No major device regulatory announcements via official channels this month

October content on SFDA’s official news channels focused mainly on drugs (breakthrough therapy designations, clinical trial initiatives, etc.); no medical device regulatory or guidance updates were found. Projects involving Saudi Arabia can proceed under existing requirements such as MDS-REQ1. As for circulating claims such as ‘local EMC testing for ultrasound equipment,’ we found no basis on official channels and are not including them this issue – for category-specific localized testing requirements, rely on written confirmation from SFDA official channels.

• Official channel: https://sfda.gov.sa/en/news

10 South Korea: Medical device reevaluation notice finalized; digital health oversight tightens

(1) Verified: Advance notice of the draft results of Medical Device Reevaluation No. 2025-93

In October, the ‘Notice’ section of the MFDS website published the advance notice of draft results for the reevaluation of medical devices listed under Order No. 2025-93, releasing the draft results for public awareness before finalization. Companies holding registrations for the affected devices in Korea should watch the impact of the reevaluation results on the continuing validity of their licenses.

• Official source: https://www.mfds.go.kr/brd/m_74/list.do (‘Notice’ section)

(2) Partially verified: Three developments including the Digital Combination Product Integrated Review Procedure Manual

According to reports by several mainstream Korean industry media on October 30, citing MFDS announcements: (1) the manual for the one-stop integrated review procedure for ‘digital combination products’ (drugs + digital medical devices) took effect, establishing the joint drug-device review team system – the manual can be found in the ‘Applicant Guide’ section of the MFDS website, though we have not yet obtained a direct link; (2) on October 28, the National Institute of Food and Drug Safety Evaluation published its 2026 status report on digital medical device approval reviews, with 13 related guidance documents published or revised within the year, and explicitly added SBOM (software bill of materials) to cybersecurity review elements; (3) certain Class II devices closely tied to daily life (hearing aids, dental implants, etc.) gained a new ‘one-stop’ certification application route, cutting processing time from about 40 days to about 25 days. All three items are corroborated by multiple independent media and are highly credible, but direct links were not obtained; they are marked as partially verified – rely on MFDS official originals for details.

III. Emerging Markets Brief

Verified against official originals

Malaysia

Item: Validity period system for product classification letters

Date: Effective October 1

One-line summary: Newly issued classification letters carry a uniform 5-year validity; existing letters older than 5 years have a 1-year transition period (until October 1, 2027); information changes require a new application rather than a renewal. We have published a dedicated analysis earlier

Official link

MDA announcement: https://portal.mda.gov.my/index.php/announcement/1857-announcement-subject-update-on-product-classification-application-system-and-implementation-of-validity-period-for-product-classification-letter

Our take:

Malaysia

Item: Consultation on third-edition drafts of GD-0068/GD-0070

Date: Published October 21

One-line summary: Updates to the two core conformity assessment (verification pathway) guidance documents; comment period until November 4

Official link

MDA announcement: https://portal.mda.gov.my/index.php/announcement/1866-announcement-public-consultation-on-updated-draft-guidance-documents-third-edition-2

Singapore

Item: GN-15 R15 registration guidance + MD-01 R1 submission checklist

Date: Implemented October 1

One-line summary: The pre-market submission checklist becomes a formal requirement for Class B/C/D registration routes; ISO 13485 certification bodies must be accredited under ILAC/IAF arrangements or be EU notified bodies. We have published a dedicated analysis earlier

Official link

GN-15 R15:

Our take:

Singapore

Item: SAR registration support initiative

Date: Recurring (October 1 – December 31 window each year)

One-line summary: Encourages unregistered devices imported via the Special Access Route (SAR) to convert to full registration; eligible applicants receive fee reductions

Official link

HSA website: https://www.hsa.gov.sg/medical-devices/registration-of-medical-devices/special-access-routes/registration-support-initiative-to-encourage-registration-of-unregistered-medical-devices-accessed-through-sar/

Indonesia

Item: Marketing authorization guideline for software-based medical devices (KMK HK.01.07/MENKES/951/2026)

Date: Published October 20

One-line summary: A written regulatory framework for SaMD/SiMD/AI medical devices: software lifecycle quality management, AI technical documentation, local clinical validation, change control and post-market surveillance. We have published a dedicated analysis earlier

Official link

Original text: https://regalkes.kemkes.go.id/index.php/home/fileDownload/BERITA_FILE.pdf/1001055

Our take:

Vietnam

Item: Decision on designation of CSDT review bodies (3046/QD-BYT)

Date: Issued September 30, implemented through October

One-line summary: CSDT technical review bodies designated separately for IVDs and non-IVDs; review fees paid by applicants directly to the review body. We have published a dedicated analysis earlier

Official link

Original text: https://vimda.moh.gov.vn/documents/10182/10030597/QD3046.CSDT/22bf4d88-e4a5-45f8-9095-0914bd4d9a54

Our take:

Argentina

Item: New guideline for GMP certificates of foreign manufacturers (Disposicion 6403/2026)

Date: Published in the Official Gazette October 6, effective October 7

One-line summary: Guideline and uniform certificate template for GMP certificates of foreign device/IVD manufacturers: ISO 13485 certificates must be issued by bodies accredited under ILAC/IAF arrangements; INPM initial review takes 40 business days (clock stops for deficiency letters/inspections); renewal applications may be filed 60 business days before expiry

Official link: Official Gazette record (ANMAT Disposicion 6403/2026, BO 06/10/2026)

India

Item: Draft guidance for IVD manufacturers open for public comment

Date: Posted October 9

One-line summary: CDSCO published the ‘Draft Guidance document for Manufacturers of In-vitro Diagnostic Medical Device’ in its official Public Notices section for stakeholder comment (1,567 KB) – an update of India’s official operational framework for IVD manufacturing/import licensing

Official link

CDSCO announcement page: https://www.boletinoficial.gob.ar/

Pakistan

Item: Notice on development of the medical devices module on the Pakistan Single Window (PSW)

Date: October 17

One-line summary: DRAP published the notice ‘Development of Medical Devices Module on PSW’ in the medical devices section of its website, announcing construction of the medical devices module on the Pakistan Single Window (PSW) system with official documents on device import clearance attached – the single-window era of electronic device import/export declarations is approaching

Official link

DRAP notice: https://www.dra.gov.pk/news_updates/regulatory_updates/medical_devices/development-of-medical-devices-module-on-psw/

Philippines

Item: Draft regulations on the FDA regulatory inspection model open for comment

Date: Issued September 30, comment period until October 26

One-line summary: The Philippine FDA opened public consultation on draft regulations for the ‘Regulatory Inspection Model for FDA-regulated health product establishments,’ introducing on-site, remote, and hybrid inspection modes – companies exporting to the Philippines may face remote inspections in the future

Official link

FDA draft page:

Items with limited verification (verification process and conclusions attached)

We were unable to fully verify the following items against official originals, but this is not a mere list of leads – for each item we actually carried out verification (direct access to official websites, page-by-page review of official notice boards, domain-restricted searches, multi-source cross-checking), and we present the verification process and conclusions as they are:

• India – October 12 notice on the extension for Class C/D device licenses:

• Content: Companies with pending Class C/D device import/manufacturing license applications already filed with the Central Licensing Authority (CLA) are deemed to have valid applications and may continue importing/manufacturing until 6 months from the date of the order or until the CLA makes its decision, whichever comes first. Background: India had originally required that Class C/D devices (ventilators, imaging equipment, surgical robots, linear accelerators, etc.) could not be sold without licenses from October 1. Verification process and conclusion: Direct connections to the CDSCO website were reset repeatedly (local network access restricted), and no direct link to the notice was found in the official Public Notices page or the Circulars section; however, multiple mainstream outlets (The Economic Times, Business Standard, Outlook Business) quoted the notice verbatim and consistently, and the coordinator of the Indian device industry association AiMeD confirmed it to media by name. Conclusion: the notice is highly credible, but no official direct link was verified – companies with pending Class C/D applications in India should obtain the original notice from CDSCO through their Indian Authorized Representative before making compliance arrangements.
• South Korea – three developments including the Digital Combination Product Integrated Review Procedure Manual: verification status as in core market section 10 above (partially verified: another notice confirmed on the official notice board; the manual cross-corroborated by multiple mainstream Korean media on the day of publication and locatable in the official guidance section; no direct link obtained).
• Russia – rumored procurement restriction list: we checked the Roszdravnadzor website directly (accessible; homepage and news list pages reviewed page by page) and found no medical device registration regulatory announcements in October – the official-channel conclusion for this issue is ‘no updates.’ The industry claim that ‘balloon catheters, bare-metal coronary stents, and drug-eluting stents were added to the list of foreign devices subject to procurement restrictions’ was not verified against official originals; Russian government procurement lists are issued separately by Russian government departments – companies selling into Russian public channels should verify with their Russian authorized representative.
• Egypt – rumored consultation on the fourth edition of the registration change guideline: to be re-checked next issue; rely on local authorized representative channels for Egypt projects.

Markets checked on official channels with no device regulatory updates this month

• Russia: The Roszdravnadzor website (roszdravnadzor.gov.ru) was checked directly; no medical device registration regulatory updates in October news or announcements.
• Thailand: The Thai FDA English official portal (en.fda.moph.go.th) was checked; no device regulatory announcements in October (circulating leads such as ‘automatic approval of a positive list for low-risk devices’ and ‘a registration pathway for second-hand imaging equipment’ were not found on the official English portal and are not included for now).

Markets where no verifiable official updates were found this issue

Kazakhstan, Mexico, Colombia, Peru, Chile, Ecuador, the UAE, South Africa, Ethiopia, Israel, Bangladesh, Kenya – this month’s sweep found no substantive regulatory updates for these markets published via official channels in October (or the websites were unreachable/could not be verified). ‘No updates’ does not mean ‘no risk’; projects involving these markets should still proceed under current requirements, and we will continue tracking next issue.

IV. Q4 Action Recommendations for Manufacturers

• Quality systems: complete the gap self-assessment against the new GMP inspection guidance within November, focusing on critical items (***) – production license inspections and unannounced inspections are judged against the new standard from November 1.
• US-EU dual track: with the UK’s indefinite recognition of CE in place, re-run the ROI calculation with the UK added to the market list covered by your CE certificates; for EU-bound Class III/implantable products, finish the SSCP inventory and translation preparation before year-end rather than crowding against the March deadline after the December go-live.
• AI/software products: this month the US FY2027 guidance plan, UK AI regulatory reform, Australia’s digital software boundary, Indonesia’s software guideline, and China’s standalone software GMP – five markets tightening or clarifying AI/SaMD requirements simultaneously. If you make AI devices, a cross-market regulatory map review is worth doing in Q4.
• In-flight project risk screening: Japan’s DWAP outage affects submission channels; Malaysia’s classification letter validity affects existing letters; Brazil’s CP 1248 affects Class III/IV submission structure; India’s new Class C/D license policy gives a 6-month grace period to companies that already applied, but new applications follow the licensing regime in effect from October 1 – spend half a day on each and confirm item by item.

V. Verification Checklist

The verification status of every item in this report is as follows (verified November 2, 2026, Beijing time):

1. China NMPA’s four GMP inspection guidance documents (Guo Yao Jian Xie Guan [2026] No. 16)

Official source: nmpa.gov.cn

Verification status: Verified – original text checked on the official website

2. China NMPA standalone software inspection guidance (Guo Yao Jian Xie Guan [2026] No. 17)

Official source: nmpa.gov.cn

Verification status: Verified – original text checked on the official website

3. China CMDE notices No. 27/28/29/30 and 3 draft guidelines for comment

Official source: cmde.org.cn

Verification status: Verified – originals checked on the official website (No. 27 also confirmed via CMDE’s official WeChat channel)

4. US FDA final order on the 510(k) exemption for clinical toxicology test systems (91 FR 63478)

Official source: govinfo.gov

Verification status: Verified against the official original

5. US FDA focused ultrasound classification order (91 FR 63493) / infant pulse rate and oxygen saturation monitor classification order (21 CFR 870.2705)

Official source: govinfo.gov / thefederalregister.org (Federal Register mirror)

Verification status: Verified (official Federal Register text)

6. US CDRH FY2027 guidance plan and IDE eSTAR draft guidance

Official source: fda.gov / regulations.gov

Verification status: Verified against the official original

7. EU MDCG 2026-4 rev.1

Official source: health.ec.europa.eu

Verification status: Verified against the official original

8. UK indefinite recognition of CE marking, MHRA 2030 strategy, AI regulatory reform

Official source: gov.uk

Verification status: Verified against the official original

9. Japan PMDA DWAP outage announcement

Official source: pmda.go.jp

Verification status: Verified on the official website announcement

10. Australia TGA digital scribe review and CDSS exemption amendments

Official source: tga.gov.au

Verification status: Verified against the official original

11. Canada GUI-0137 v4 / GUI-0147 v2 and the MDC bulletin

Official source: canada.ca

Verification status: Verified against the official original

12. Brazil ANVISA recognized standards list, CP 1248, MDSAP consultation

Official source: gov.br/anvisa

Verification status: Verified via official channels (standards list details cross-confirmed via the official page and industry reporting)

13. Saudi Arabia SFDA October developments

Official source: sfda.gov.sa

Verification status: Verified via official channels (conclusion: no major device updates)

14. Malaysia MDA classification letter validity and GD-0068/0070 consultation

Official source: portal.mda.gov.my

Verification status: Verified against the official original

15. Singapore HSA GN-15 R15/MD-01 R1 and SAR registration support initiative

Official source: hsa.gov.sg / file.go.gov.sg

Verification status: Verified against the official original

16. Indonesia software device guideline (KMK 951/2026)

Official source: regalkes.kemkes.go.id

Verification status: Verified against the official original

17. Vietnam 3046/QD-BYT

Official source: vimda.moh.gov.vn

Verification status: Verified against the official original

18. Argentina ANMAT 6403/2026

Official source: Official Gazette (Boletin Oficial) publication record

Verification status: Verified – publication in the Gazette confirmed (published 06/10/2026, effective 07/10/2026)

19. India CDSCO draft guidance for IVD manufacturers (posted October 9)

Official source: cdsco.gov.in (official Public Notices page)

Verification status: Verified – official page entry checked (title, date, file)

20. India CDSCO notice on the Class C/D license extension (October 12)

Official source: cdsco.gov.in (access restricted from our location) | Economic Times/Business Standard/Outlook Business

Verification status: Partially verified – no official direct link found (notice quoted verbatim by multiple mainstream outlets plus named confirmation by AiMeD; highly credible)

21. Pakistan DRAP PSW devices module notice (October 17)

Official source: dra.gov.pk

Verification status: Verified against the official website (including the official PDF attachment)

22. Philippines FDA draft regulations on the inspection model (comment period until October 26)

Official source: fda.gov.ph

Verification status: Verified against the official original

23. South Korea MFDS advance notice on reevaluation No. 2025-93

Official source: mfds.go.kr (‘Notice’ section)

Verification status: Verified on the official notice board

24. South Korea: digital combination product review manual and two further developments

Official source: mfds.go.kr (‘Applicant Guide’ section) | mainstream Korean industry media

Verification status: Partially verified (section locatable on the official website, cross-corroborated by media on the day of publication; no direct link obtained)

25. Russia Roszdravnadzor October developments

Official source: roszdravnadzor.gov.ru

Verification status: Verified via official channels (conclusion: no device registration regulatory updates in October)

26. Thailand FDA English portal October developments

Official source: en.fda.moph.go.th

Verification status: Verified via official channels (conclusion: no device regulatory announcements in October)

27. Egypt EDA rumored consultation on the fourth edition of the guideline

Official source: eda.eg

Verification status: Not verified – website unreachable (to be re-checked next issue)

Note on verification methods: methods include checking official originals on authority websites, page-by-page review of official notice boards, domain-restricted searches, downloading and comparing official PDFs, and multi-source cross-checking. Rumors such as Saudi ‘local EMC testing for ultrasound equipment’ were found to have no basis on official channels and insufficient credibility of the original source; they were removed outright and are not included in this issue.

VI. Disclaimer

Disclaimer: This report is compiled from publicly available official information and is for reference only; it does not constitute legal, regulatory, or compliance advice. The specific application of regulatory provisions is subject to the current official texts published by each regulatory authority; information marked ‘not verified’ must not be used as the basis for compliance decisions.